<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Approach to the adult with interstitial lung disease: Clinical evaluation</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Approach to the adult with interstitial lung disease: Clinical evaluation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Approach to the adult with interstitial lung disease: Clinical evaluation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Talmadge E King, Jr, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin R Flaherty, MD, MS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 28, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The diffuse parenchymal lung diseases, often collectively referred to as the interstitial lung diseases (ILDs), are a heterogeneous group of disorders that are classified together because of similar clinical, radiographic, physiologic, or pathologic manifestations  (<a class="graphic graphic_algorithm graphicRef77345" href="/z/d/graphic/77345.html" rel="external">algorithm 1</a>) [<a href="#rid1">1-7</a>]. The descriptive term "interstitial" reflects the pathologic appearance that the abnormality begins in the interstitium, but the term is somewhat misleading, as most of these disorders are also associated with extensive alteration of alveolar and airway architecture.</p><p>An overview of the clinical findings that can aid in the diagnosis of ILD will be presented here  (<a class="graphic graphic_algorithm graphicRef69044" href="/z/d/graphic/69044.html" rel="external">algorithm 2</a>). The individual causes of ILD and the diagnostic testing that is helpful in evaluating patients with ILD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">"Idiopathic interstitial pneumonias: Classification and pathology"</a> and  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a> and  <a class="medical medical_review" href="/z/d/html/4315.html" rel="external">"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment"</a> and  <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">"Approach to the adult with interstitial lung disease: Diagnostic testing"</a> and  <a class="medical medical_review" href="/z/d/html/4308.html" rel="external">"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease"</a> and  <a class="medical medical_review" href="/z/d/html/4379.html" rel="external">"Role of lung biopsy in the diagnosis of interstitial lung disease"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>The diffuse parenchymal lung diseases are divided into those that are associated with known causes and those that are idiopathic. The treatment choices and prognosis vary among the different causes and types of ILD, so ascertaining the correct diagnosis is important.</p><p>A variety of infections can cause interstitial opacities on chest radiograph, including fungal pneumonias (eg, coccidioidomycosis, cryptococcosis, Pneumocystis jirovecii), atypical bacterial pneumonias, and viral pneumonias. These infections often occur in immunocompromised hosts and are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1401.html" rel="external">"Approach to the immunocompromised patient with fever and pulmonary infiltrates"</a>.)</p><p>The most common identifiable causes of ILD are exposure to occupational and environmental agents, especially to inorganic or organic dusts  (<a class="graphic graphic_table graphicRef80757 graphicRef62236" href="/z/d/graphic/80757.html" rel="external">table 1A-B</a>), drug-induced pulmonary toxicity, and radiation-induced lung injury. (See  <a class="medical medical_review" href="/z/d/html/4307.html" rel="external">"Asbestos-related pleuropulmonary disease"</a> and  <a class="medical medical_review" href="/z/d/html/4367.html" rel="external">"Chronic beryllium disease (berylliosis)"</a> and  <a class="medical medical_review" href="/z/d/html/4321.html" rel="external">"Silicosis"</a> and  <a class="medical medical_review" href="/z/d/html/4315.html" rel="external">"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment"</a> and  <a class="medical medical_review" href="/z/d/html/4331.html" rel="external">"Radiation-induced lung injury"</a> and  <a class="medical medical_review" href="/z/d/html/4309.html" rel="external">"Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Epidemiology, causes, and pathogenesis"</a>.)</p><p>ILD can also complicate the course of most of the connective tissue diseases (eg, polymyositis/dermatomyositis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, mixed connective tissue disease).</p><p>Idiopathic causes of ILD include sarcoidosis, cryptogenic organizing pneumonia, and the idiopathic interstitial pneumonias  (<a class="graphic graphic_algorithm graphicRef77345" href="/z/d/graphic/77345.html" rel="external">algorithm 1</a>). The idiopathic interstitial pneumonias have been further characterized: idiopathic pulmonary fibrosis (usual interstitial pneumonia), desquamative interstitial pneumonia, respiratory bronchiolitis-interstitial lung disease, acute interstitial pneumonia, and nonspecific interstitial pneumonia. (See  <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">"Idiopathic interstitial pneumonias: Classification and pathology"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Patients with ILD commonly come to clinical attention in one of the following ways:</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms of progressive breathlessness with exertion (dyspnea) or a persistent nonproductive cough. (See  <a class="medical medical_review" href="/z/d/html/1436.html" rel="external">"Approach to the patient with dyspnea"</a> and  <a class="medical medical_review" href="/z/d/html/1460.html" rel="external">"Causes and epidemiology of subacute and chronic cough in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary symptoms associated with another disease, such as a connective tissue disease  (<a class="graphic graphic_table graphicRef64034" href="/z/d/graphic/64034.html" rel="external">table 2</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of occupational exposure (eg, asbestosis, silicosis)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An abnormal chest imaging study</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lung function abnormalities on simple office spirometry, particularly a restrictive ventilatory pattern (ie, reduced total lung capacity and forced vital capacity). (See  <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults"</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h1">HISTORY</span><span class="headingEndMark"> — </span>The most important step in the initial evaluation of a patient with suspected interstitial lung disease is obtaining a complete history. Careful documentation of the past medical history is important in the initial assessment because the cause of the illness is often recognized from the patient's history. In addition to a thorough review of past systemic conditions and HIV risk factors, several other aspects of the history are particularly important and include the following features.</p><p class="headingAnchor" id="H5"><span class="h2">Age and gender</span><span class="headingEndMark"> — </span>Some of the ILDs are more common in certain age groups or have a male or female predominance. For example, the majority of patients with sarcoidosis, connective tissue disease-associated ILD, lymphangioleiomyomatosis, pulmonary Langerhans cell histiocytosis, and inherited forms of ILD (familial IPF, Gaucher's disease, Hermansky-Pudlak syndrome) present between the ages of 20 and 40 years. In contrast, most patients with idiopathic pulmonary fibrosis (IPF, also called cryptogenic fibrosing alveolitis in Europe) are over age 50.</p><p>Lymphangioleiomyomatosis and pulmonary involvement in tuberous sclerosis occur exclusively in premenopausal women. Other diseases with a less pronounced female preponderance include lymphocytic interstitial pneumonitis, ILD in Hermansky-Pudlak syndrome, and the connective tissue diseases [<a href="#rid8">8,9</a>]. In contrast, ILD associated with rheumatoid arthritis is more common in men. Because of occupational exposures, men are also more likely to have a pneumoconiosis.</p><p class="headingAnchor" id="H6"><span class="h2">Onset of symptoms</span><span class="headingEndMark"> — </span>The duration of symptoms prior to presentation may help focus the differential diagnosis. The acute or subacute processes (eg, acute eosinophilic pneumonia, cryptogenic organizing pneumonia, connective tissue associated ILD) often share features with atypical infectious pneumonias, such as the rapid onset of symptoms, diffuse radiographic opacities, and fever  (<a class="graphic graphic_table graphicRef80410" href="/z/d/graphic/80410.html" rel="external">table 3</a>).</p><p>ILDs with a chronic or indolent presentation (eg, idiopathic pulmonary fibrosis, sarcoidosis, pneumoconioses) need to be differentiated from each other and from diseases such as chronic obstructive pulmonary disease and heart failure.</p><p>Some ILDs, such as hypersensitivity pneumonitis and sarcoidosis, may have an acute, subacute, or chronic presentation. (See  <a class="medical medical_review" href="/z/d/html/4313.html" rel="external">"Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Past medical history</span><span class="headingEndMark"> — </span>Any history of connective tissue disease, inflammatory bowel disease, or malignancy might be a clue to an associated ILD, either due to the underlying disease or to medications used to treat the disease  (<a class="graphic graphic_table graphicRef56668" href="/z/d/graphic/56668.html" rel="external">table 4</a>). A number of medications used to treat cardiac disease have also been associated with ILD, notably <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>. A history of allergic rhinitis and asthma may implicate chronic eosinophilic pneumonia, while nasal polyposis and asthma may suggest eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss). An immunocompromised state due to an underlying disease or immunomodulatory therapy may suggest an infectious cause of ILD.</p><p class="headingAnchor" id="H8"><span class="h2">Smoking history</span><span class="headingEndMark"> — </span>A history of tobacco use is important, since some diseases occur largely among current or former smokers (eg, pulmonary Langerhans cell histiocytosis, desquamative interstitial pneumonitis, respiratory bronchiolitis-interstitial lung disease, and idiopathic pulmonary fibrosis) or among never or former smokers (eg, sarcoidosis and hypersensitivity pneumonitis).</p><p>Active smoking can contribute to complications in patients with Goodpasture's syndrome, in which pulmonary hemorrhage is far more frequent among current smokers. In this setting, it is thought that smoking damages the alveolar wall, making the alveolar basement membrane more accessible to the circulating antibasement membrane antibodies [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/3108.html" rel="external">"Anti-GBM (Goodpasture) disease: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Family history</span><span class="headingEndMark"> — </span>The family history is occasionally helpful, as several familial associations have been identified [<a href="#rid11">11-15</a>]. However, different types of ILD (eg, idiopathic pulmonary fibrosis and nonspecific interstitial pneumonitis) may occur within a single family [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/z/d/html/4300.html" rel="external">"Pathogenesis of idiopathic pulmonary fibrosis", section on 'Genetic predisposition'</a>.)</p><p>Familial aggregation and racial differences in incidence support the notion that sarcoidosis occurs in genetically susceptible hosts. However, the familial sarcoidosis studies clearly exclude a simple mode of inheritance, suggesting a more complex genetic background. (See  <a class="medical medical_review" href="/z/d/html/4365.html" rel="external">"Pathology and pathogenesis of sarcoidosis", section on 'Possible etiologic agents'</a>.)</p><p>An autosomal dominant pattern of inheritance has been reported for familial pulmonary fibrosis (FPF), tuberous sclerosis, and neurofibromatosis (see  <a class="medical medical_review" href="/z/d/html/4300.html" rel="external">"Pathogenesis of idiopathic pulmonary fibrosis", section on 'Genetic predisposition'</a> and  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis", section on 'Pathogenesis'</a> and  <a class="medical medical_review" href="/z/d/html/142618.html" rel="external">"Tuberous sclerosis complex: Genetics and pathogenesis", section on 'Genetics'</a>). In a study of 111 families with two or more cases of pulmonary fibrosis, 20 pedigrees demonstrated vertical transmission, consistent with autosomal dominant inheritance, and 45 demonstrated phenotypic heterogeneity [<a href="#rid16">16</a>]. Having ever smoked cigarettes was strongly associated with the development of pulmonary fibrosis, suggesting that an interaction between environmental exposure and gene or gene(s) may contribute to the pathogenesis of this disease.</p><p>An autosomal recessive pattern of inheritance has been identified for Niemann-Pick disease, Gaucher's disease, and Hermansky-Pudlak syndrome [<a href="#rid17">17,18</a>]. (See  <a class="medical medical_review" href="/z/d/html/6196.html" rel="external">"Overview of Niemann-Pick disease"</a> and  <a class="medical medical_review" href="/z/d/html/2918.html" rel="external">"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/115158.html" rel="external">"Hermansky-Pudlak syndrome"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Prior medication use and irradiation</span><span class="headingEndMark"> — </span>A detailed history of all medications taken and any exposure to therapeutic irradiation is needed to exclude the possibility of drug-induced or radiation-induced lung disease [<a href="#rid19">19-21</a>]. The medication history should include over-the-counter medications, oily nose drops or petroleum products, and amino acid supplements  (<a class="graphic graphic_table graphicRef56668" href="/z/d/graphic/56668.html" rel="external">table 4</a>) [<a href="#rid19">19,20</a>]. In some cases, lung disease may occur weeks to years after the drug has been discontinued (eg, <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">carmustine</a>). (See  <a class="medical medical_review" href="/z/d/html/4315.html" rel="external">"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment"</a> and  <a class="medical medical_review" href="/z/d/html/4354.html" rel="external">"Nitrosourea-induced pulmonary injury"</a>.)</p><p>A list of drugs reported to cause pulmonary toxicity is available at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.pneumotox.com%2Fdrug%2Findex%2F&amp;token=xXI%2By9QNEPjV52%2B%2BDeHAebUs0tWBJH2E4P6NjJKXt7lfaz85Ary5D81ipOGXzyNa&amp;TOPIC_ID=4310" target="_blank">Pneumotox</a>.</p><p>Radiation-induced lung injury is directly related to the volume of irradiated lung and the cumulative dose of irradiation. Symptoms associated with acute radiation pneumonitis usually develop approximately four to twelve weeks following irradiation, whereas symptoms of late or fibrotic radiation pneumonitis develop after six to twelve months. Radiation recall pneumonitis can occur months to years after irradiation, when certain antineoplastic agents (eg, Adriamycin, <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">gemcitabine</a>, <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a>) are administered to a patient who has received prior radiation therapy to the lung. (See  <a class="medical medical_review" href="/z/d/html/4331.html" rel="external">"Radiation-induced lung injury"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Occupational and environmental exposures</span><span class="headingEndMark"> — </span>Review of the home and work environment, including that of spouse and children, is invaluable [<a href="#rid22">22-27</a>]. A strict chronological listing of the patient's entire lifelong employment must be sought, including specific duties and known exposures to dusts, gases, and chemicals [<a href="#rid22">22</a>]. The degree of exposure, duration, latency of exposure, and the use of protective devices should be elicited. The patient may need to obtain material safety data sheets (MSDS) from the employer, if it is unclear what exposures may have occurred in the workplace. A written questionnaire can be used to obtain this information in a systematic manner  (<a class="graphic graphic_table graphicRef80757 graphicRef62236" href="/z/d/graphic/80757.html" rel="external">table 1A-B</a>). (See  <a class="medical medical_review" href="/z/d/html/4313.html" rel="external">"Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/4321.html" rel="external">"Silicosis", section on 'Silica in the work environment'</a> and  <a class="medical medical_review" href="/z/d/html/4307.html" rel="external">"Asbestos-related pleuropulmonary disease", section on 'Asbestos exposure'</a> and  <a class="medical medical_review" href="/z/d/html/4367.html" rel="external">"Chronic beryllium disease (berylliosis)", section on 'Risk factors'</a>.)</p><p>In hypersensitivity pneumonitis (extrinsic allergic alveolitis), the development of respiratory symptoms, fever, chills, and an abnormal chest radiograph are often temporally related to the workplace (farmer's lung) or to a hobby (pigeon breeder's disease). Symptoms may diminish or disappear after the patient leaves the exposure for several days and often reappear upon returning to the exposure. Thus, it is important to determine if the patient has had exposures to pets (especially any birds), air conditioners, humidifiers, hot tubs, evaporative cooling systems (eg, swamp coolers), or if there has been water damage to walls and carpets in the home or work environment. Family members may develop disease as a result of "passive" exposure to dusts from the hobby or occupation of another member of the family (eg, asbestosis, berylliosis). (See  <a class="medical medical_review" href="/z/d/html/4309.html" rel="external">"Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Epidemiology, causes, and pathogenesis"</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Symptoms</span><span class="headingEndMark"> — </span>Patients with ILD can present with a number of symptoms, and it is important to ascertain the duration, severity, and progression of symptoms. Most of the symptoms are nonspecific, but some will help to narrow the differential. In particular, patients should be asked about extrapulmonary symptoms that might suggest a systemic disorder.</p><p class="bulletIndent1"><span class="glyph">●</span>Dyspnea – A sense of shortness of breath, ie, dyspnea, is a common complaint of patients with cardiac or pulmonary disease [<a href="#rid28">28</a>]. In most instances, the patient has attributed the insidious onset of breathlessness with exertion to aging, deconditioning, obesity, or a previous unresolved upper respiratory tract illness. Some patients deny the presence of dyspnea even when questioned. This usually occurs because they have limited their activity and therefore rarely experience any significant discomfort. Frequently, a spouse or friend brings the problem to the patient's attention.</p><p></p><p>Grading the level of dyspnea is useful as a method to gauge the severity of the disease and to follow its course  (<a class="graphic graphic_table graphicRef55810" href="/z/d/graphic/55810.html" rel="external">table 5</a>) [<a href="#rid29">29</a>]. However, some patients, especially those with sarcoidosis, silicosis, or pulmonary Langerhans cell histiocytosis, may have extensive parenchymal lung disease on chest radiograph <strong>without</strong> significant dyspnea. This most often occurs early in the course of the disease. (See  <a class="medical medical_review" href="/z/d/html/1436.html" rel="external">"Approach to the patient with dyspnea"</a> and  <a class="medical medical_review" href="/z/d/html/1427.html" rel="external">"Physiology of dyspnea"</a>.)</p><p>Sudden worsening of dyspnea, particularly if associated with pleural pain, may indicate a spontaneous pneumothorax. Spontaneous pneumothorax is a characteristic finding that may occur in diseases such as pulmonary Langerhans cell histiocytosis, tuberous sclerosis, lymphangioleiomyomatosis, and neurofibromatosis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cough</strong> – A dry cough is common and can be particularly bothersome in conditions that involve the airways, such as sarcoidosis, bronchiolitis obliterans with or without organizing pneumonia, respiratory bronchiolitis, pulmonary Langerhans cell histiocytosis, hypersensitivity pneumonitis, lipoid pneumonia, and lymphangitic carcinomatosis [<a href="#rid30">30</a>]. A productive cough is <strong>unusual</strong> for most ILDs; rarely, a mucoid, salty-tasting sputum is reported by patients with bronchoalveolar cell carcinoma. (See  <a class="medical medical_review" href="/z/d/html/1460.html" rel="external">"Causes and epidemiology of subacute and chronic cough in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis", section on 'Typical presentations'</a> and  <a class="medical medical_review" href="/z/d/html/4323.html" rel="external">"Overview of bronchiolar disorders in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4313.html" rel="external">"Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">"Cryptogenic organizing pneumonia"</a> and  <a class="medical medical_review" href="/z/d/html/4334.html" rel="external">"Pulmonary Langerhans cell histiocytosis"</a> and  <a class="medical medical_review" href="/z/d/html/4319.html" rel="external">"Respiratory bronchiolitis-associated interstitial lung disease"</a> and  <a class="medical medical_review" href="/z/d/html/7024.html" rel="external">"Aspiration pneumonia in adults", section on 'Lipoid pneumonia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemoptysis</strong> – Grossly bloody or blood-streaked sputum may occur in the diffuse alveolar hemorrhage syndromes, lymphangioleiomyomatosis, tuberous sclerosis, pulmonary veno-occlusive disease, longstanding mitral valve disease, and granulomatous vasculitides. In some patients, diffuse alveolar bleeding may be present without hemoptysis; the clinical manifestations in such patients may be dyspnea and an iron deficiency anemia. The new onset of hemoptysis in a patient with known ILD suggests a complicating malignancy. (See  <a class="medical medical_review" href="/z/d/html/4333.html" rel="external">"Evaluation of nonlife-threatening hemoptysis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Wheezing</strong> – Wheezing is an uncommon manifestation of ILD. It has been described in cases of lymphangitic carcinomatosis, chronic eosinophilic pneumonia, EGPA, and respiratory bronchiolitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chest pain</strong> – Chest pain is uncommon in most ILDs. However, pleuritic chest pain may occur in ILD associated with rheumatoid arthritis, systemic lupus erythematosus, mixed connective tissue disease, and some drug-induced disorders. In addition, the acute onset of pleuritic chest pain may indicate a pneumothorax. Substernal discomfort or pain is common in sarcoidosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extrapulmonary symptoms</strong> – Clinical findings suggestive of a connective tissue disease should be carefully recorded. These include musculoskeletal pain, weakness, fatigue, fever, joint pains or swelling, photosensitivity, Raynaud phenomenon, pleuritis, dry eyes, and dry mouth. However, the absence of these symptoms does not exclude connective tissue disease, as the pulmonary manifestations occasionally precede the more typical systemic manifestations by months or years (especially in rheumatoid arthritis, systemic lupus erythematosus, and polymyositis-dermatomyositis).</p><p></p><p class="headingAnchor" id="H13"><span class="h1">PHYSICAL EXAMINATION</span><span class="headingEndMark"> — </span>The physical examination of patients with ILD is usually nonspecific, except when extrapulmonary findings suggest a particular systemic disease.</p><p class="headingAnchor" id="H14"><span class="h2">Lung examination</span><span class="headingEndMark"> — </span>The lung examination is frequently abnormal in ILD, but the findings are generally nonspecific. Crackles or "velcro râles" are present on chest examination in most forms of ILD, although they are less likely to be heard in the granulomatous lung diseases, especially sarcoidosis [<a href="#rid31">31</a>]. Crackles may be present in the absence of radiographic abnormalities on the chest radiograph. When listening for crackles in patients with suspected ILD, it is helpful to listen at the lung bases in the posterior axillary line, as crackles may be audible only in this location in early disease.</p><p>Scattered late inspiratory high-pitched rhonchi, so-called inspiratory squeaks, are frequently heard on chest examination in patients with bronchiolitis, but may also be heard in patients with traction bronchiectasis due to pulmonary fibrosis.</p><p class="headingAnchor" id="H15"><span class="h2">Cardiac examination</span><span class="headingEndMark"> — </span>The cardiac examination is usually normal except in more advanced stages of pulmonary fibrosis, when findings of pulmonary hypertension and cor pulmonale (augmented P2, right-sided lift, right-sided gallop) may become evident. Pulmonary hypertension may also be a primary manifestation of some connective tissue disorders (eg, progressive systemic sclerosis).</p><p>Findings of cor pulmonale (eg, peripheral edema, right ventricular heave, accentuated second heart sound) are rare in ILD. When present, these findings are usually indicative of advanced disease. (See  <a class="medical medical_review" href="/z/d/html/8262.html" rel="external">"Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Epidemiology, pathogenesis, and diagnostic evaluation in adults", section on 'Clinical evaluation'</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Clubbing</span><span class="headingEndMark"> — </span>Clubbing of the digits  (<a class="graphic graphic_figure graphicRef52839" href="/z/d/graphic/52839.html" rel="external">figure 1</a>) is common in some pulmonary disorders (idiopathic pulmonary fibrosis, asbestosis) and rare in others (sarcoidosis, hypersensitivity pneumonitis, pulmonary Langerhans cell histiocytosis). Other disorders associated with clubbing include cystic fibrosis, pulmonary arteriovenous malformations, cyanotic heart disease, malignancies of the lung and pleura, and inflammatory bowel disease [<a href="#rid32">32</a>]. When clubbing occurs in the course of ILD, it is typically a late manifestation and suggests advanced fibrosis of the lung. The pathophysiology of clubbing is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5615.html" rel="external">"Malignancy and rheumatic disorders", section on 'Hypertrophic osteoarthropathy'</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Extrapulmonary findings of systemic disease</span><span class="headingEndMark"> — </span>The identification of extrapulmonary manifestations of diseases such as amyloidosis, connective tissue diseases, Hermansky-Pudlak syndrome, neurofibromatosis, sarcoidosis, or tuberous sclerosis can help to narrow the differential diagnosis  (<a class="graphic graphic_table graphicRef73094" href="/z/d/graphic/73094.html" rel="external">table 6</a>). In particular, patients are examined for evidence of alopecia, angiofibromas, cutaneous sarcoidosis, Gottron's papules  (<a class="graphic graphic_picture graphicRef70904 graphicRef50909 graphicRef51110" href="/z/d/graphic/70904.html" rel="external">picture 1A-C</a>), heliotrope rash  (<a class="graphic graphic_picture graphicRef73090 graphicRef53713" href="/z/d/graphic/73090.html" rel="external">picture 2A-B</a>), joint inflammation, "mechanics" hands, muscle weakness, nasal obstruction, peripheral neuropathy, and sclerodactyly. Nailfold capillary microscopy may help with early identification of connective tissue disease in patients who report Raynaud phenomenon [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/7543.html" rel="external">"Clinical manifestations and diagnosis of Raynaud phenomenon", section on 'Nailfold capillary microscopy'</a>.)</p><p class="headingAnchor" id="H2932302272"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118793.html" rel="external">"Society guideline links: Interstitial lung disease"</a>.)</p><p class="headingAnchor" id="H97464620"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/83031.html" rel="external">"Patient education: Idiopathic pulmonary fibrosis (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/86972.html" rel="external">"Patient education: Interstitial lung disease (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification and approach</strong> – Diffuse parenchymal lung diseases, often collectively referred to as interstitial lung diseases (ILDs), are divided into those that are associated with known causes and those that are idiopathic  (<a class="graphic graphic_algorithm graphicRef77345" href="/z/d/graphic/77345.html" rel="external">algorithm 1</a>). An approach to evaluating immunocompetent patients with ILD is shown in the algorithm  (<a class="graphic graphic_algorithm graphicRef69044" href="/z/d/graphic/69044.html" rel="external">algorithm 2</a>). (See <a class="local">'Introduction'</a> above and <a class="local">'Classification'</a> above.)</p><p></p><p class="bulletIndent1">A variety of infectious processes (eg, atypical bacterial, viral, and fungal pneumonia) can cause opacities on chest radiograph that mimic ILD. These infections often occur in immunocompromised hosts and are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1401.html" rel="external">"Approach to the immunocompromised patient with fever and pulmonary infiltrates"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation and history</strong> – The initial recognition that a patient may have an ILD usually follows the onset of progressive breathlessness with exertion (dyspnea), a persistent nonproductive cough, or pulmonary symptoms associated with another disease, such as a connective tissue disease  (<a class="graphic graphic_table graphicRef64034" href="/z/d/graphic/64034.html" rel="external">table 2</a>). (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1">Careful documentation of the past medical history is important in the initial assessment because the cause of the illness is often recognized from the patient's medical history. Attention is also given to history of smoking, medication use, occupational and environmental exposures, and familial occurrence of ILD  (<a class="graphic graphic_table graphicRef80757 graphicRef62236" href="/z/d/graphic/80757.html" rel="external">table 1A-B</a>). (See <a class="local">'History'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical examination</strong> – Crackles, also described as "velcro râles," are a nonspecific finding present in most forms of ILD, although they are less likely to be heard in the granulomatous lung diseases, especially sarcoidosis. Crackles may be present in the absence of radiographic abnormalities on the chest radiograph. (See <a class="local">'Physical examination'</a> above.)</p><p></p><p class="bulletIndent1">Clubbing of the digits is common in some ILDs (idiopathic pulmonary fibrosis, asbestosis) and rare in others (sarcoidosis, hypersensitivity pneumonitis, pulmonary Langerhans cell histiocytosis)  (<a class="graphic graphic_figure graphicRef52839" href="/z/d/graphic/52839.html" rel="external">figure 1</a>). (See <a class="local">'Physical examination'</a> above.)</p><p></p><p class="bulletIndent1">An important part of the physical examination of patients with an undiagnosed ILD is looking for extrapulmonary evidence of a systemic disease that might be associated with ILD  (<a class="graphic graphic_table graphicRef64034" href="/z/d/graphic/64034.html" rel="external">table 2</a>). (See <a class="local">'Extrapulmonary findings of systemic disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic testing</strong> – The diagnostic testing (eg, laboratory tests, imaging studies, bronchoalveolar lavage, and lung biopsy) that is helpful in evaluating patients with ILD is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">"Approach to the adult with interstitial lung disease: Diagnostic testing"</a> and  <a class="medical medical_review" href="/z/d/html/4308.html" rel="external">"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease"</a> and  <a class="medical medical_review" href="/z/d/html/4379.html" rel="external">"Role of lung biopsy in the diagnosis of interstitial lung disease"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Schwartz M, King Jr TE. Interstitial Lung disease, 5th ed, People's Medical Clearing House, Shelton, CT 2011.</li><li><a class="nounderline abstract_t">Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788.</a></li><li><a class="nounderline abstract_t">American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165:277.</a></li><li><a class="nounderline abstract_t">King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378:1949.</a></li><li><a class="nounderline abstract_t">Travis WD, Hunninghake G, King TE Jr, et al. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med 2008; 177:1338.</a></li><li><a class="nounderline abstract_t">Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63 Suppl 5:v1.</a></li><li><a class="nounderline abstract_t">Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2018; 198:e44.</a></li><li><a class="nounderline abstract_t">Pierson DM, Ionescu D, Qing G, et al. Pulmonary fibrosis in hermansky-pudlak syndrome. a case report and review. Respiration 2006; 73:382.</a></li><li><a class="nounderline abstract_t">Tian X, Yi ES, Ryu JH. Lymphocytic interstitial pneumonia and other benign lymphoid disorders. Semin Respir Crit Care Med 2012; 33:450.</a></li><li><a class="nounderline abstract_t">Donaghy M, Rees AJ. Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane. Lancet 1983; 2:1390.</a></li><li><a class="nounderline abstract_t">Garcia CK, Raghu G. Inherited interstitial lung disease. Clin Chest Med 2004; 25:421.</a></li><li><a class="nounderline abstract_t">Marshall RP, Puddicombe A, Cookson WO, Laurent GJ. Adult familial cryptogenic fibrosing alveolitis in the United Kingdom. Thorax 2000; 55:143.</a></li><li><a class="nounderline abstract_t">Diaz de Leon A, Cronkhite JT, Katzenstein AL, et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One 2010; 5:e10680.</a></li><li><a class="nounderline abstract_t">Alder JK, Chen JJ, Lancaster L, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci U S A 2008; 105:13051.</a></li><li><a class="nounderline abstract_t">Grutters JC, du Bois RM. Genetics of fibrosing lung diseases. Eur Respir J 2005; 25:915.</a></li><li><a class="nounderline abstract_t">Steele MP, Speer MC, Loyd JE, et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 2005; 172:1146.</a></li><li><a class="nounderline abstract_t">Borie R, Crestani B, Guyard A, Lidove O. Interstitial lung disease in lysosomal storage disorders. Eur Respir Rev 2021; 30.</a></li><li><a class="nounderline abstract_t">Velázquez-Díaz P, Nakajima E, Sorkhdini P, et al. Hermansky-Pudlak Syndrome and Lung Disease: Pathogenesis and Therapeutics. Front Pharmacol 2021; 12:644671.</a></li><li><a class="nounderline abstract_t">Camus P, Bonniaud P, Fanton A, et al. Drug-induced and iatrogenic infiltrative lung disease. Clin Chest Med 2004; 25:479.</a></li><li class="breakAll">Camus P. Drug-induced interstitial lung disease. In: Interstitial Lung Disease, 4th ed, King TE Jr, Schwarz MI (Eds), B.C. Decker, Hamilton, ON, Canada 2003. p.485.</li><li><a class="nounderline abstract_t">Fernández AB, Karas RH, Alsheikh-Ali AA, Thompson PD. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports. Chest 2008; 134:824.</a></li><li><a class="nounderline abstract_t">Glazer CS, Newman LS. Occupational interstitial lung disease. Clin Chest Med 2004; 25:467.</a></li><li><a class="nounderline abstract_t">Selman M, Pardo A, King TE Jr. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med 2012; 186:314.</a></li><li><a class="nounderline abstract_t">Sirajuddin A, Kanne JP. Occupational lung disease. J Thorac Imaging 2009; 24:310.</a></li><li><a class="nounderline abstract_t">Sauler M, Gulati M. Newly recognized occupational and environmental causes of chronic terminal airways and parenchymal lung disease. Clin Chest Med 2012; 33:667.</a></li><li><a class="nounderline abstract_t">Koster MA, Thomson CC, Collins BF, et al. Diagnosis of Hypersensitivity Pneumonitis in Adults, 2020 Clinical Practice Guideline: Summary for Clinicians. Ann Am Thorac Soc 2021; 18:559.</a></li><li><a class="nounderline abstract_t">Dodia N, Amariei D, Kenaa B, et al. A comprehensive assessment of environmental exposures and the medical history guides multidisciplinary discussion in interstitial lung disease. Respir Med 2021; 179:106333.</a></li><li><a class="nounderline abstract_t">Schwartzstein RM. Are you fluent in the 'language' of dyspnea? J Respir Dis 1996; 17:322.</a></li><li><a class="nounderline abstract_t">Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 2012; 185:435.</a></li><li><a class="nounderline abstract_t">Morice AH, Millqvist E, Bieksiene K, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J 2020; 55.</a></li><li><a class="nounderline abstract_t">Bohadana A, Izbicki G, Kraman SS. Fundamentals of lung auscultation. N Engl J Med 2014; 370:744.</a></li><li><a class="nounderline abstract_t">Spicknall KE, Zirwas MJ, English JC 3rd. Clubbing: an update on diagnosis, differential diagnosis, pathophysiology, and clinical relevance. J Am Acad Dermatol 2005; 52:1020.</a></li><li><a class="nounderline abstract_t">Umashankar E, Abdel-Shaheed C, Plit M, Girgis L. Assessing the role for nailfold videocapillaroscopy in interstitial lung disease classfication: a systematic review and meta-analysis. Rheumatology (Oxford) 2022; 61:2221.</a></li></ol></div><div id="topicVersionRevision">Topic 4310 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Schwartz M, King Jr TE. Interstitial Lung disease, 5th ed, People's Medical Clearing House, Shelton, CT 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21471066" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11790668" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21719092" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18388353" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18757459" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30168753" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16490934" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pulmonary fibrosis in hermansky-pudlak syndrome. a case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23001800" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Lymphocytic interstitial pneumonia and other benign lymphoid disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6140495" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15331184" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Inherited interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10639533" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Adult familial cryptogenic fibrosing alveolitis in the United Kingdom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20502709" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18753630" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Short telomeres are a risk factor for idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15863652" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Genetics of fibrosing lung diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16109978" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical and pathologic features of familial interstitial pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33927007" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Interstitial lung disease in lysosomal storage disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33841163" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hermansky-Pudlak Syndrome and Lung Disease: Pathogenesis and Therapeutics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15331188" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Drug-induced and iatrogenic infiltrative lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15331188" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Drug-induced and iatrogenic infiltrative lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18689579" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15331187" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Occupational interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22679012" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19935227" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Occupational lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23153608" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Newly recognized occupational and environmental causes of chronic terminal airways and parenchymal lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33141595" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Diagnosis of Hypersensitivity Pneumonitis in Adults, 2020 Clinical Practice Guideline: Summary for Clinicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33676119" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A comprehensive assessment of environmental exposures and the medical history guides multidisciplinary discussion in interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Are you fluent in the 'language' of dyspnea?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22336677" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31515408" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : ERS guidelines on the diagnosis and treatment of chronic cough in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24552321" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Fundamentals of lung auscultation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15928621" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clubbing: an update on diagnosis, differential diagnosis, pathophysiology, and clinical relevance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34668513" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Assessing the role for nailfold videocapillaroscopy in interstitial lung disease classfication: a systematic review and meta-analysis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
